{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:40:05Z","timestamp":1780584005822,"version":"3.54.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670189"],"award-info":[{"award-number":["81670189"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81471165"],"award-info":[{"award-number":["81471165"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013061","name":"Jilin Provincial Scientific and Technological Development Program","doi-asserted-by":"publisher","award":["20190201163JC"],"award-info":[{"award-number":["20190201163JC"]}],"id":[{"id":"10.13039\/501100013061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013061","name":"Jilin Provincial Scientific and Technological Development Program","doi-asserted-by":"publisher","award":["20190201042JC"],"award-info":[{"award-number":["20190201042JC"]}],"id":[{"id":"10.13039\/501100013061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01723-0","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:16:21Z","timestamp":1752538581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Development and validation of a prognostic staging system for primary plasma cell leukemia"],"prefix":"10.1186","volume":"18","author":[{"given":"Mengru","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijun","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunrui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aili","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqing","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuling","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingcheng","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2285-0818","authenticated-orcid":false,"given":"Yun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2288-556X","authenticated-orcid":false,"given":"Fengyan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"issue":"2","key":"1723_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41375-023-02100-x","volume":"38","author":"L Saba","year":"2024","unstructured":"Saba L, Landau KS, Liang H, Fu C-L, Chaulagain CP. Real world analysis on the determinants of survival in primary plasma cell leukemia in the united States. Leukemia. 2024;38(2):435\u20137.","journal-title":"Leukemia"},{"issue":"2","key":"1723_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41408-021-00414-6","volume":"11","author":"SA Tuazon","year":"2021","unstructured":"Tuazon SA, Holmberg LA, Nadeem O, Richardson PG. A clinical perspective on plasma cell leukemia; current status and future directions. Blood Cancer J. 2021;11(2):23.","journal-title":"Blood Cancer J"},{"issue":"17","key":"1723_CR3","doi-asserted-by":"publisher","first-page":"e70192","DOI":"10.1002\/cam4.70192","volume":"13","author":"C Tessier","year":"2024","unstructured":"Tessier C, LeBlanc R, Roy J, et al. Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia. Cancer Med. 2024;13(17):e70192.","journal-title":"Cancer Med"},{"issue":"4","key":"1723_CR4","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/leu.2012.336","volume":"27","author":"CF de Larrea","year":"2013","unstructured":"de Larrea CF, Kyle RA, Durie BG, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the international myeloma working group. Leukemia. 2013;27(4):780\u201391.","journal-title":"Leukemia"},{"issue":"6","key":"1723_CR5","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3324\/haematol.2016.158303","volume":"102","author":"M Granell","year":"2017","unstructured":"Granell M, Calvo X, Garcia-Gui\u00f1\u00f3n A, et al. Prognostic impact of Circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica. 2017;102(6):1099\u2013104.","journal-title":"Haematologica"},{"issue":"12","key":"1723_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-018-0140-1","volume":"8","author":"P Ravi","year":"2018","unstructured":"Ravi P, Kumar SK, Roeker L, et al. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo clinic study with comparison of outcomes to multiple myeloma. Blood Cancer J. 2018;8(12):116.","journal-title":"Blood Cancer J"},{"issue":"9","key":"1723_CR7","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1038\/s41375-018-0209-7","volume":"32","author":"M Gavriatopoulou","year":"2018","unstructured":"Gavriatopoulou M, Musto P, Caers J, et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018;32(9):1883\u201398.","journal-title":"Leukemia"},{"issue":"4","key":"1723_CR8","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.annonc.2025.01.022","volume":"36","author":"P Musto","year":"2025","unstructured":"Musto P, Engelhardt M, van de Donk NWCJ, et al. European myeloma network group review and consensus statement on primary plasma cell leukemia. Ann Oncol. 2025;36(4):361\u201374.","journal-title":"Ann Oncol"},{"issue":"12","key":"1723_CR9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","volume":"11","author":"FC de Larrea","year":"2021","unstructured":"de Larrea FC, Kyle R, Rosi\u00f1ol L, et al. Primary plasma cell leukemia: consensus definition by the international myeloma working group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021;11(12):192.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1723_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/ejh.12533","volume":"95","author":"T Jelinek","year":"2015","unstructured":"Jelinek T, Kryukov F, Rihova L, Hajek R. Plasma cell leukemia: from biology to treatment. Eur J Haematol. 2015;95(1):16\u201326.","journal-title":"Eur J Haematol"},{"issue":"11","key":"1723_CR11","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2012.107","volume":"26","author":"SZ Usmani","year":"2012","unstructured":"Usmani SZ, Nair B, Qu P, et al. Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with total therapy protocols. Leukemia. 2012;26(11):2398\u2013405.","journal-title":"Leukemia"},{"key":"1723_CR12","doi-asserted-by":"publisher","first-page":"106687","DOI":"10.1016\/j.leukres.2021.106687","volume":"111","author":"K Gowin","year":"2021","unstructured":"Gowin K, Skerget S, Keats JJ, Mikhael J, Cowan AJ. Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment. Leu Res. 2021;111:106687.","journal-title":"Leu Res"},{"issue":"6","key":"1723_CR13","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.3390\/cancers14061594","volume":"14","author":"EA Rojas","year":"2022","unstructured":"Rojas EA, Guti\u00e9rrez NC. Genomics of plasma cell leukemia. Cancers. 2022;14(6):1594.","journal-title":"Cancers"},{"issue":"17","key":"1723_CR14","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1182\/blood.2021014968","volume":"139","author":"T Cazaubiel","year":"2022","unstructured":"Cazaubiel T, Leleu X, Perrot A, et al. Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features. Blood. 2022;139(17):2666\u201372.","journal-title":"Blood"},{"key":"1723_CR15","doi-asserted-by":"crossref","unstructured":"Nandakumar B, Kumar SK, Dispenzieri A et al. Clinical characteristics and outcomes of patients with primary plasma cell leukemia in the era of novel agent therapy. Mayo Clin Proc. 2021;96(3):677\u201387.","DOI":"10.1016\/j.mayocp.2020.06.060"},{"issue":"26","key":"1723_CR16","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. J Clin Oncol. 2015;33(26):2863\u20139.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1723_CR17","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/bjh.15092","volume":"180","author":"A Jurczyszyn","year":"2018","unstructured":"Jurczyszyn A, Radocha J, Davila J, et al. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. Br J Haematol. 2018;180(6):831\u20139.","journal-title":"Br J Haematol"},{"issue":"7","key":"1723_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","volume":"15","author":"SK Kumar","year":"2018","unstructured":"Kumar SK, Rajkumar SV. The multiple myelomas \u2014 current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol. 2018;15(7):409\u201321.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"1723_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/ajh.26774","volume":"98","author":"P Yang","year":"2023","unstructured":"Yang P, Chen H, Liang X, et al. Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma. Am J Hematol. 2023;98(2):251\u201363.","journal-title":"Am J Hematol"},{"issue":"2","key":"1723_CR20","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/sim.8779","volume":"40","author":"C Wallisch","year":"2020","unstructured":"Wallisch C, Dunkler D, Rauch G, et al. Selection of variables for multivariable models: opportunities and limitations in quantifying model stability by resampling. Stat Med. 2020;40(2):369\u201381.","journal-title":"Stat Med"},{"issue":"12","key":"1723_CR21","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348.","journal-title":"Lancet Oncol"},{"issue":"29","key":"1723_CR22","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Jos\u00b4e Lahuerta J, et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: A European myeloma network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40(29):3406\u201318.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1723_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41408-022-00611-x","volume":"12","author":"NH Abdallah","year":"2022","unstructured":"Abdallah NH, Binder M, Rajkumar SV, et al. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022;12(1):21.","journal-title":"Blood Cancer J"},{"issue":"12","key":"1723_CR24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41408-019-0253-1","volume":"9","author":"EA Rojas","year":"2019","unstructured":"Rojas EA, Corchete LA, Mateos MV, Garc\u00eda-Sanz R, Misiewicz-Krzeminska I, Guti\u00e9rrez NC. Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background. Blood Cancer J. 2019;9(12):90.","journal-title":"Blood Cancer J"},{"issue":"12","key":"1723_CR25","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1158\/1078-0432.CCR-12-3461","volume":"19","author":"K Todoerti","year":"2013","unstructured":"Todoerti K, Agnelli L, Fabris S, et al. Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. Clin Cancer Res. 2013;19(12):3247\u201358.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1723_CR26","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1084\/jem.20182031","volume":"216","author":"K Tretina","year":"2019","unstructured":"Tretina K, Park E-S, Maminska A, et al. Interferon-induced guanylate-binding proteins: guardians of host defense in health and disease. J Exp Med. 2019;216(3):482\u2013500.","journal-title":"J Exp Med"},{"key":"1723_CR27","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.3389\/fimmu.2017.01908","volume":"8","author":"C Xia","year":"2018","unstructured":"Xia C, Braunstein Z, Toomey AC, Zhong J, Rao X. S100 proteins as an important regulator of macrophage inflammation. Front Immunol. 2018;8:1908.","journal-title":"Front Immunol"},{"issue":"1","key":"1723_CR28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12903","volume":"297","author":"P Kumari","year":"2020","unstructured":"Kumari P, Russo AJ, Shivcharan S, Rathinam VA. AIM2 in health and disease: inflammasome and beyond. Immunol Rev. 2020;297(1):83\u201395.","journal-title":"Immunol Rev"},{"issue":"12","key":"1723_CR29","doi-asserted-by":"publisher","first-page":"113476","DOI":"10.1016\/j.celrep.2023.113476","volume":"42","author":"P Davidovich","year":"2023","unstructured":"Davidovich P, Higgins CA, Najda Z, Longley DB, Martin SJ. cFLIPL acts as a suppressor of TRAIL- and Fas-initiated inflammation by inhibiting assembly of caspase-8\/FADD\/RIPK1 NF-\u03baB-activating complexes. Cell Rep. 2023;42(12):113476.","journal-title":"Cell Rep"},{"issue":"22","key":"1723_CR30","doi-asserted-by":"publisher","first-page":"5758","DOI":"10.1158\/0008-5472.CAN-19-1366","volume":"79","author":"Y Xiao","year":"2019","unstructured":"Xiao Y, Zhao H, Tian L, et al. S100A10 is a critical mediator of GAS6\/AXL-induced angiogenesis in renal cell carcinoma. Cancer Res. 2019;79(22):5758\u201368.","journal-title":"Cancer Res"},{"issue":"6","key":"1723_CR31","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3390\/jpm11060535","volume":"11","author":"B Almuzzaini","year":"2021","unstructured":"Almuzzaini B, Alghamdi J, Alomani A, et al. Identification of novel mutations in colorectal cancer patients using ampliseq comprehensive Cancer panel. J Pers Med. 2021;11(6):535.","journal-title":"J Pers Med"},{"issue":"1","key":"1723_CR32","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1182\/hematology.2022000347","volume":"2022","author":"TM Schmidt","year":"2022","unstructured":"Schmidt TM. High or low? Assessing disease risk in multiple myeloma. Hematol Am Soc Hematol Educ Program. 2022;2022(1):349\u201355.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"1723_CR33","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/leu.2011.176","volume":"26","author":"H Avet-Loiseau","year":"2012","unstructured":"Avet-Loiseau H, Roussel M, Campion L, et al. Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience. Leukemia. 2012;26(1):158\u20139.","journal-title":"Leukemia"},{"issue":"6","key":"1723_CR34","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41408-020-0336-z","volume":"10","author":"C Schinke","year":"2020","unstructured":"Schinke C, Boyle EM, Ashby C, et al. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. Blood Cancer J. 2020;10(6):70.","journal-title":"Blood Cancer J"},{"issue":"2","key":"1723_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3390\/biomedicines10020209","volume":"10","author":"SI Papadhimitriou","year":"2022","unstructured":"Papadhimitriou SI, Terpos E, Liapis K, et al. The cytogenetic profile of primary and secondary plasma cell leukemia: etiopathogenetic perspectives, prognostic impact and clinical relevance to newly diagnosed multiple myeloma with differential Circulating clonal plasma cells. Biomedicines. 2022;10(2):209.","journal-title":"Biomedicines"},{"issue":"24","key":"1723_CR36","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the international myeloma working group. Blood. 2016;127(24):2955\u201362.","journal-title":"Blood"},{"issue":"9","key":"1723_CR37","doi-asserted-by":"publisher","first-page":"e600","DOI":"10.1038\/bcj.2017.83","volume":"7","author":"M Binder","year":"2017","unstructured":"Binder M, Rajkumar SV, Ketterling RP, et al. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. Blood Cancer J. 2017;7(9):e600.","journal-title":"Blood Cancer J"},{"issue":"3","key":"1723_CR38","first-page":"21","volume":"13","author":"WI Gonsalves","year":"2017","unstructured":"Gonsalves WI. Primary plasma cell leukemia: A practical approach to diagnosis and clinical management. Am J Hematol Oncol. 2017;13(3):21\u20135.","journal-title":"Am J Hematol Oncol"},{"issue":"7","key":"1723_CR39","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1200\/JCO.22.01226","volume":"41","author":"T Jelinek","year":"2022","unstructured":"Jelinek T, Bezdekova R, Zihala D, et al. More than 2% of Circulating tumor plasma cells defines plasma cell leukemia-like multiple myeloma. J Clin Oncol. 2022;41(7):1383\u201392.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1723_CR40","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1007\/s00277-023-05362-8","volume":"102","author":"M Tian","year":"2023","unstructured":"Tian M, Liang X, Xu W, et al. More than 2% Circulating plasma cells as a prognostic biomarker in a large cohort of patients with newly-diagnosed multiple myeloma. Ann Hematol. 2023;102(10):2943\u20135.","journal-title":"Ann Hematol"},{"issue":"4","key":"1723_CR41","doi-asserted-by":"publisher","first-page":"475","DOI":"10.4274\/jcrpe.galenos.2021.2021.0099","volume":"14","author":"B Yeter","year":"2022","unstructured":"Yeter B, Aslanger AD, Ye\u015fil G, El\u00e7io\u011flu NH. A novel mutation in the TRIP11 gene: diagnostic approach from relatively common skeletal dysplasias to an extremely rare odontochondrodysplasia. J Clin Res Pediatr Endocrinol. 2022;14(4):475\u201380.","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"30","key":"1723_CR42","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.1038\/s41388-019-0844-0","volume":"38","author":"J Marcus","year":"2019","unstructured":"Marcus J, Bejerano-Sagie M, Patterson N, et al. Septin 9 isoforms promote tumorigenesis in mammary epithelial cells by increasing migration and ECM degradation through metalloproteinase secretion at focal adhesions. Oncogene. 2019;38(30):5839\u201359.","journal-title":"Oncogene"},{"issue":"2","key":"1723_CR43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.trecan.2018.12.002","volume":"5","author":"J Tasoulas","year":"2019","unstructured":"Tasoulas J, Rodon L, Kaye FJ, Montminy M, Amelio AL. Adaptive transcriptional responses by CRTC coactivators in cancer. Trends Cancer. 2019;5(2):111\u201327.","journal-title":"Trends Cancer"},{"issue":"19","key":"1723_CR44","doi-asserted-by":"publisher","first-page":"17543","DOI":"10.18632\/oncotarget.4028","volume":"6","author":"I Cifola","year":"2015","unstructured":"Cifola I, Lionetti M, Pinatel E, et al. Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. Oncotarget. 2015;6(19):17543\u201358.","journal-title":"Oncotarget"},{"issue":"27","key":"1723_CR45","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1200\/JCO.21.01217","volume":"40","author":"DHO Bruinink","year":"2022","unstructured":"Bruinink DHO, Kuiper R, van Duin M, et al. Identification of high-risk multiple myeloma with a plasma cell leukemia-like transcriptomic profile. J Clin Oncol. 2022;40(27):3132\u201350.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1723_CR46","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1158\/1078-0432.CCR-19-0694","volume":"26","author":"D Ryu","year":"2020","unstructured":"Ryu D, Kim SJ, Hong Y, et al. Alterations in the transcriptional programs of myeloma cells and the microenvironment during extramedullary progression affect proliferation and immune evasion. Clin Cancer Res. 2020;26(4):935\u201344.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1723_CR47","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/ajh.26891","volume":"98","author":"E Katodritou","year":"2023","unstructured":"Katodritou E, Kastritis E, Dalampira D, et al. Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group. Am J Hematol. 2023;98(5):730\u20138.","journal-title":"Am J Hematol"},{"issue":"10","key":"1723_CR48","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S1470-2045(23)00405-9","volume":"24","author":"NWCJ van de Donk","year":"2023","unstructured":"van de Donk NWCJ, Minnema MC, van der Holt B, et al. Treatment of primary plasma cell leukaemia with Carfilzomib and lenalidomide-based therapy (EMN12\/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study. Lancet Oncol. 2023;24(10):1119\u201333.","journal-title":"Lancet Oncol"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01723-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01723-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01723-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T10:50:34Z","timestamp":1757242234000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01723-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1723"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01723-0","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior presentation"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial information"}},{"value":"The study was approved by the Institutional Review Boards (IRBs) of the First Hospital of Jilin University (Approval # 2020-080). All patients had given written informed consent to the use of clinical data and diagnostic samples for research.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"72"}}